絞り込み

18453

広告

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning.

著者 Kanakry CG , O'Donnell PV , Furlong T , de Lima MJ , Wei W , Medeot M , Mielcarek M , Champlin RE , Jones RJ , Thall PF , Andersson BS , Luznik L
J Clin Oncol.2014 Sep 29 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (43view , 0users)
The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of severe acute and chronic GVHD, low toxicity, and effective disease control.
PMID: 25267759 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード